期刊论文

中文

中国实验方剂学杂志

1005-9903

2018

24

6

161-166

10.13422/j.cnki.syfjx.20180685

81373602:国家自然科学基金 81774287:国家自然科学基金 2017CT5029:中央引导地方科技发展专项 201604:湖南省中医药研究院重点项目

本校为第一机构

目的:观察健脾消癌方对结肠癌SW620细胞中转化生长因子-β(transforming growth factor-β,TGF-β)/长链非编码RNA-ATB(long noncoding RNA ATB,lncRNA-ATB)/微小RNA 200a(microRNA 200a,miR-200a)信号通路的影响,探讨健脾消癌方抑制结直肠癌转移的可能作用机制。方法:10%,15%,20%健脾消癌方含药血清处理TGF-β诱导后SW620细胞,实时定量荧光聚合酶链式反应(Real-time polymerase chain reaction,Real-time PCR)检测lncRNA-ATB,miR-200a,E盒结合锌指蛋白(Zinc finger E-box-binding homeobox 1,ZEB1)mRNA的表达水平,蛋白质免疫印迹法(Western blot)检测ZEB1蛋白表达水平。结果:与空白组比较,TGF-...

Objective:To observe the effect of Jianpi Xiaoai prescription (JPXAD) on the transforming growth factor-β (TGF-β)/ long noncoding RNA-ATB (lncRNA-ATB)/ microRNA 200a (miR-200a) signal pathway in colon cancer cells SW620, in order to study the anti-metastatic effect of JPXAD in colorectal cancer. Method: The 10%, 15%, 20% JPXAD-containing serum was given to SW620 cells after the treatment with TGF-β, Real-time PCR was applied to detect the mRNA expressions of lncRNA-ATB, miR-200a and Zinc finger E-box-binding homeobox 1(ZEB1), and Western blo...